Oropharyngeal carcinoma
Conditions
Interventions
Case series:Platinum-based combined chemotherapy regimens
concurrent chemotherapy regimens use cisplatin monotherapy
Sponsors
Affiliated Hospital of Guizhou Medical Universityou Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years old; 2. Squamous cell carcinoma of oropharynx (including root of tongue, tonsil, soft palate and posterior wall of pharynx) confirmed by pathology, detected by p16 immunohistochemistry or HPV in situ hybridization; 3. CT3, cN0-1 (single lymph node metastasis 3 cm, or 2 and multiple ipsilateral lymph node metastases =70; 5. Before treatment, there are imaging data such as oropharyngeal CT/MRI (including functional MRI sequence), which can be used to measure tumor lesions; 6. This treatment must be the initial treatment, without surgical treatment (except biopsy); 7. Expected survival of not less than 6 months; 8. The patients in the group also need to meet the following clinical laboratory standards: hemoglobin > 100 g/L. Granulocytes are not less than 1.5x10^9/L and platelets are not less than 100x10^9/L. All the indexes of liver and kidney function are within 1.5 times of the upper limit of the normal value; 9. Be able to understand this study and have signed an informed consent form; 10. Be able to complete the follow-up.
Exclusion criteria
Exclusion criteria: 1. Previously suffered from other malignant tumors (except cured cervical carcinoma in situ, gastrointestinal mucosa cancer, breast cancer and non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane); 2. Those who received tumor-related treatment before enrollment; 3. pregnant or lactating women, women of childbearing age who are not contraceptive; 4. Those who are undergoing other drug trials; 5. Patients with severe comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer, psychosis and uncontrollable diabetes, etc.; 6. Those without regular follow-up conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Explore the target area delineation of Gross tumor volum (GTV) after induction chemotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Observe the effect of this method on the target area and the dose of normal tissues; observe the patient's toxic and side effects, quality of life (quality of life scale; dysphagia scale), and clinical efficacy.; | — |
Countries
China
Contacts
Public ContactLi Yuanyuan
Guizhou Cancer Hospital
Outcome results
None listed